2021.09.08 Press release

--To the press -

FRONTEO reports management medical device sales business

Direct sales of AI medical devices from FRONTEO to medical institutions, etc.

FRONTEO Inc.
Masahiro Morimoto, President and CEO
東京 都 港区 港 南 2-12-23
(Code number: 2158 TSE Mothers)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) submitted a notification to the Tokyo Metropolitan Government on September 9 for the management medical equipment sales business and was accepted (Notification number: 7 Minato Misei Equipment No. 3).

 

 FRONTEO obtained a first-class medical device manufacturing and sales license from Tokyo in January 2021 (license number: 1B13X1).The medical device manufacturing and sales business ships and markets medical devices as stipulated in the "Act on Securing Quality, Effectiveness, and Safety of Pharmaceuticals and Medical Devices" (commonly known as the Pharmaceutical Machinery Law), and the effectiveness of products.・ It is a business format that is responsible for safety and quality.The medical device sales business notified this time is a business format that provides medical devices supplied by manufacturers and distributors to medical institutions and users directly or through other companies.With the acquisition of the first-class medical device manufacturing and sales license and the notification of the managed medical device sales business, it has become possible to distribute and sell the medical devices shipped and marketed by FRONTEO to medical institutions.

 

 FRONTEO is currently conducting clinical trials to obtain manufacturing and marketing approval for the AI ​​medical device "Conversational Dementia Diagnosis Support AI Program."Maximize the value of AI medical devices by notifying the managed medical device sales business and building an in-house distribution system to promote the early commercialization of AI medical devices such as this program and their utilization in medical settings. I will plan.

 


■ About conversational dementia diagnosis support AI program

 URL:https://lifescience.fronteo.com/aidevice/dementia/
The "Conversational Dementia Diagnosis Support Program" (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder (trademark: conceptencoder, reading: concept encoder)" between doctors and patients. It is a system that can screen for cognitive dysfunction from daily conversation for about 5 minutes. FRONTEO believes that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which has entered a super-aging society. I am. We started clinical trials in April 10 and are currently working toward early manufacturing and marketing approval and early launch.Patent registration number: Patent No. 2021

■ About Concept Encoder 
 URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the self-developed AI engine "KIBIT" and "Concept Encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. , A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge" , Drug discovery support, dementia diagnosis support, financial / personnel / sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, conceptencoder, and KIBIT are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc.

E-mail: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x